Search results
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 days agoHalozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript May 7, 2024 Halozyme...
Bavencio Side Effects: What They Are and How to Manage Them
Healthline· 4 days agoBavencio (avelumab) is a prescription drug used to treat certain types of kidney, bladder, and skin cancer. Bavencio can cause side effects that range from mild to serious. Examples include ...
Q1 2024 Nuwellis Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 3 days agoWe are honored to be working with them as their heart failure program is one of the largest in Michigan, Dr. Jennifer Culver, Head of the heart failure program will lead the efforts, and ...
Journey Medical Corp Announces New Journey with the Experts Video Featuring Karan Lal, DO
Digital Journal· 12 hours agoJourney Medical Corporation (NASDAQ:DERM) ("Journey Medical") today released a new Journey with the Experts video featuring Karan Lal, DO, a double board-certified pediatric and cosmetic dermatologist ...
Q1 2024 Bio Rad Laboratories Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 3 days agoThe second agreement is a collaboration with Oncocyte to commercialize their Advanced Transplant Monitoring Assays deploying Bio-Rad's QX600 Droplet Digital PCR...by the initial ...
Q1 2024 Halozyme Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 3 days agoWe're also pleased to report two pipeline advancements. Firstly, our Agennix...
Inside Madrigal's 'full speed' launch of its groundbreaking NASH drug Rezdiffra - Philadelphia...
The Business Journals· 3 days agoIn the seven weeks since Madrigal Pharmaceuticals became the first drug developer to receive Food...
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
StreetInsider· 4 days agoReaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of...
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at...
WPRI Providence· 3 days agoLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European ...
Minuteful Kidney From Healthy.io Named "Best Overall Mobile Health Solution" in 2024 MedTech...
Fontana Herald News· 2 days agoHealthy.io, the global leader in transforming the smartphone camera into a medical device, today announced that Minuteful Kidney has been selected as "Best Overall Mobile Health Solution" in ...
